公开(公告)号：US12029714B2

公开(公告)日：2024-07-09

申请号：US18095354

申请日：2023-01-10

Applicant: Seth Feuerstein

Inventor： Seth Feuerstein

IPC: A61M21/02 ,  A61B5/16 ,  A61K31/202 ,  A61K31/437 ,  A61K31/4985 ,  A61K36/35 ,  A61K45/06 ,  A61M21/00

CPC classification number: A61K31/202 ,  A61B5/165 ,  A61K31/437 ,  A61K31/4985 ,  A61K36/35 ,  A61K45/06 ,  A61M21/00 ,  A61M21/02 ,  A61K31/437 ,  A61K2300/00 ,  A61K31/4985 ,  A61K2300/00

Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments the pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and nonpharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.

公开(公告)号：US12023369B2

公开(公告)日：2024-07-02

申请号：US17552499

申请日：2021-12-16

Applicant: GELITA AG

Inventor： Steffen Oesser ,  Stephan Hausmanns ,  Hans-Ulrich Frech

IPC: A61K38/00 ,  A23L2/00 ,  A23L33/00 ,  A23L33/18 ,  A61K8/65 ,  A61K9/00 ,  A61K31/122 ,  A61K31/4745 ,  A61K35/36 ,  A61K36/77 ,  A61K36/82 ,  A61K38/01 ,  A61K38/06 ,  A61K38/39 ,  A61K38/44 ,  A61P3/02 ,  A61Q19/06

CPC classification number: A61K38/39 ,  A23L2/00 ,  A23L33/18 ,  A23L33/30 ,  A61K8/65 ,  A61K9/0053 ,  A61K31/122 ,  A61K31/4745 ,  A61K35/36 ,  A61K36/77 ,  A61K36/82 ,  A61K38/011 ,  A61K38/014 ,  A61K38/063 ,  A61K38/446 ,  A61P3/02 ,  A61Q19/06 ,  A61K2800/92 ,  A61K38/063 ,  A61K2300/00 ,  A61K38/446 ,  A61K2300/00 ,  A61K38/014 ,  A61K2300/00 ,  A61K38/011 ,  A61K2300/00 ,  A61K36/82 ,  A61K2300/00 ,  A61K36/77 ,  A61K2300/00 ,  A61K35/36 ,  A61K2300/00 ,  A61K31/122 ,  A61K2300/00 ,  A61K31/4745 ,  A61K2300/00

Abstract: The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.

公开(公告)号：US12023352B2

公开(公告)日：2024-07-02

申请号：US16741627

申请日：2020-01-13

Applicant: Antnor Limited

Inventor： Anthony Galea ,  Irina Brokhman

IPC: A61K35/14 ,  A61K38/18 ,  A61K38/20 ,  C07K1/14 ,  C12N9/64

CPC classification number: A61K35/14 ,  A61K38/1841 ,  A61K38/1858 ,  A61K38/1866 ,  A61K38/2006 ,  C07K1/14 ,  C12N9/64 ,  A61K38/1841 ,  A61K2300/00 ,  A61K38/1858 ,  A61K2300/00 ,  A61K38/1866 ,  A61K2300/00

Abstract: Described are methods of producing an autologous composition useful for treatment of damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a mammal. The method comprises preparing an anti-inflammatory/anti-catabolic component of the autologous composition comprising IL-1ra and TIMPs. An anti-inflammatory/anti-catabolic component is prepared comprising: collecting blood from the mammal; delivering the blood to a tube; incubating the blood at a temperature of from about 37° C. to about 39° C. for about 24 hours, preferably in the presence of sodium citrate; centrifuging the blood to separate the blood into a supernatant component and a cellular fraction; and collecting the supernatant component. The method further comprises the step of preparing a regenerative component of the autologous composition comprising: collecting blood from the mammal; delivering the blood to a tube in the presence of about 4% citric acid; centrifuging the blood to separate a platelet-rich plasma component from a whole blood; collecting the platelet-rich plasma component; and mixing the supernatant component with the platelet-rich plasma component to provide the autologous composition. Also provided is a method of treating damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a subject with the autologous composition, an autologous composition for treating damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a mammal and the use of the autologous composition for the treatment of damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a mammal.

公开(公告)号：US12016872B2

公开(公告)日：2024-06-25

申请号：US17022560

申请日：2020-09-16

Applicant: Nant Holdings IP, LLC

Inventor： Patrick Soon-Shiong

IPC: A61K31/7036 ,  A61K31/05 ,  A61K31/19 ,  A61K31/203 ,  A61K31/352 ,  A61K31/4035 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/454 ,  A61K31/513 ,  A61K31/519 ,  A61K31/573 ,  A61K31/65 ,  A61K31/706 ,  A61K45/06 ,  G01N33/574

CPC classification number: A61K31/7036 ,  A61K31/05 ,  A61K31/19 ,  A61K31/203 ,  A61K31/352 ,  A61K31/4035 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/454 ,  A61K31/513 ,  A61K31/519 ,  A61K31/573 ,  A61K31/65 ,  A61K31/706 ,  A61K45/06 ,  G01N33/574 ,  G01N33/57488 ,  G01N2800/52 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/7036 ,  A61K2300/00 ,  A61K31/203 ,  A61K2300/00 ,  A61K31/65 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00 ,  A61K31/4035 ,  A61K2300/00 ,  A61K31/706 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00 ,  A61K31/352 ,  A61K2300/00

Abstract: Compositions and methods for treatment of a condition associated with disease stem cells, and especially cancer stem cells are disclosed. In one aspect, a patient is treated with a stem cell differentiating agent and/or teratogenic pharmaceutical compound to induce one or more destructive pathways in the disease stem cells. Most typically, the destructive pathways include apoptotic pathways, necrotic pathways, and autophagy pathways.

公开(公告)号：US12011476B2

公开(公告)日：2024-06-18

申请号：US15931809

申请日：2020-05-14

Applicant: The University of Vermont and State Agricultural College

Inventor： Yvonne M. Janssen-Heininger ,  Vikas Anathy

IPC: A61K38/12 ,  A61K31/197 ,  A61K31/425 ,  A61K31/437 ,  A61K31/713 ,  A61K38/06 ,  A61K38/16 ,  A61K38/45 ,  A61K45/06 ,  C12N15/113

CPC classification number: A61K38/12 ,  A61K31/197 ,  A61K31/425 ,  A61K31/437 ,  A61K31/713 ,  A61K38/06 ,  A61K38/164 ,  A61K38/45 ,  A61K45/06 ,  C12N15/113 ,  C12N15/1137 ,  C12N2310/14 ,  C12Y205/01018 ,  C12Y503/04001 ,  A61K31/425 ,  A61K2300/00 ,  A61K31/437 ,  A61K2300/00

Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

公开(公告)号：US12011463B2

公开(公告)日：2024-06-18

申请号：US16933492

申请日：2020-07-20

Applicant: Reapplix ApS

Inventor： Rasmus Lundquist ,  Niels Erik Holm

IPC: A61K35/19 ,  A61K35/15 ,  A61K35/33 ,  A61K38/15 ,  A61K38/17 ,  A61K38/36 ,  A61L24/10 ,  B04B5/04 ,  C12N5/078 ,  C12N5/0787 ,  G01N33/49 ,  A61L26/00 ,  A61M1/02

CPC classification number: A61K35/19 ,  A61K35/15 ,  A61K35/33 ,  A61K38/15 ,  A61K38/17 ,  A61K38/36 ,  A61K38/363 ,  A61L24/106 ,  B04B5/04 ,  C12N5/0642 ,  C12N5/0644 ,  G01N33/49 ,  A61L26/0042 ,  A61M1/029 ,  B04B2005/0485 ,  C12N2501/905 ,  G01N33/491 ,  A61K38/363 ,  A61K2300/00 ,  A61K38/15 ,  A61K2300/00 ,  A61K38/17 ,  A61K2300/00 ,  A61K35/19 ,  A61K2300/00 ,  A61K35/15 ,  A61K2300/00

Abstract: A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.

公开(公告)号：US12005057B2

公开(公告)日：2024-06-11

申请号：US15986536

申请日：2018-05-22

Applicant: TESARO, INC.

Inventor： Mary Lynne Hedley ,  Robert Martell

IPC: A61K31/454 ,  A61K31/4745 ,  A61P35/00 ,  A61K9/48 ,  C12Q1/6886

CPC classification number: A61K31/454 ,  A61K31/4745 ,  A61P35/00 ,  A61K9/48 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K31/454 ,  A61K2300/00 ,  A61K31/4745 ,  A61K2300/00

Abstract: The present invention provides methods of administering a PARP inhibitor to a cancer patient.

公开(公告)号：US11999747B2

公开(公告)日：2024-06-04

申请号：US17146327

申请日：2021-01-11

Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH

Inventor： Linkun An ,  Christophe Marchand ,  Yves Pommier

IPC: A61K31/343 ,  A61K31/122 ,  A61K31/136 ,  A61K31/194 ,  A61K31/47 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/704 ,  A61K31/7048 ,  A61K45/06 ,  C07D221/08 ,  C07D307/92 ,  C07D471/04 ,  C07D491/04 ,  C07D491/048 ,  C07D498/04

CPC classification number: C07D491/048 ,  A61K31/122 ,  A61K31/136 ,  A61K31/194 ,  A61K31/343 ,  A61K31/47 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/704 ,  A61K31/7048 ,  A61K45/06 ,  C07D221/08 ,  C07D307/92 ,  C07D471/04 ,  C07D491/04 ,  C07D498/04 ,  A61K31/122 ,  A61K2300/00 ,  A61K31/136 ,  A61K2300/00 ,  A61K31/194 ,  A61K2300/00 ,  A61K31/473 ,  A61K2300/00 ,  A61K31/475 ,  A61K2300/00 ,  A61K31/704 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/47 ,  A61K2300/00 ,  A61K31/498 ,  A61K2300/00

Abstract: Compounds of Formula I and the pharmaceutically acceptable salts thereof are disclosed




The variables X1, X2, and R1-4 are disclosed herein. The compounds are useful for treating cancer and related proliferative diseases. Pharmaceutical compositions containing compounds of Formula I and methods of treatment comprising administering compounds of Formula I are also disclosed.

公开(公告)号：US11993597B2

公开(公告)日：2024-05-28

申请号：US17692026

申请日：2022-03-10

Applicant: Amgen Inc.

Inventor： Brian Alan Lanman ,  Shon Booker ,  Clifford Goodman ,  Anthony B. Reed ,  Jonathan D. Low ,  Hui-Ling Wang ,  Ning Chen ,  Ana Elena Minatti ,  Ryan Wurz ,  Victor J. Cee

IPC: C07D471/04 ,  A61K31/519 ,  A61P35/00 ,  A61K31/7068 ,  A61K38/07

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61P35/00 ,  A61K31/7068 ,  A61K38/07 ,  A61K2300/00

Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

公开(公告)号：US20240165063A1

公开(公告)日：2024-05-23

申请号：US18230601

申请日：2023-08-04

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  USWM, LLC

Inventor： Eugene Gerner ,  Elizabeth Bruckheimer

IPC: A61K31/198 ,  A61K31/192 ,  A61K31/203 ,  A61K31/415 ,  A61K31/616 ,  A61K31/69 ,  A61K31/7048 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/30 ,  C12Q1/6886

CPC classification number: A61K31/198 ,  A61K31/192 ,  A61K31/203 ,  A61K31/415 ,  A61K31/616 ,  A61K31/69 ,  A61K31/7048 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/3084 ,  C12Q1/6886 ,  A61K2039/505 ,  A61K2300/00 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention provides methods and kits a) for preventing and/or treating neuroblastoma (e.g., high-risk neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patients whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and/or +316 of the ODC1 gene. The invention also provides, cancer treatment methods comprising the determination of the ODC1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection, which includes, in some aspects the administration of pharmaceutically effective amounts of α-difluoromethylornithine (DFMO), either as a monotherapy or in combination with one or more other drugs. In addition, the present invention provides methods for preventing and/or treating patients that have been determined to have cancer stem cells, such as patients in cancer remission that are at risk for relapse.